Read Our News And Press Releases

Read our news and press releases

As a business striving for growth, Halberd is rapidly changing. This means that we have many stories to tell, we like to share them with you.

Oct 1 2024

Halberd & Athena GTX Report Initial Success of WatchDawg® PTSD Treatment Pilot Study

By Admin|2024-11-28T06:29:43-05:00October 1st, 2024|Featured, Investor News, Press Releases|0 Comments

Ten Military Veteran Volunteers Participated in the Pilot Study Enabled by Athena GTX Health Monitoring System Jackson Center, PA October 1, 2024 – Halberd Corporation (OTC-PINK: "HALB”) released the results of the recently completed WatchDawg® Pilot Study. Ten (10) military veteran participated in the study where they received pharmaceuticals (LDX) and nutraceuticals, along with 24/7 ...

Sep 11 2024

Halberd Partnership Secures Contract from Defense Atomics Corporation to Address Brain Injury and PTSD

By Admin|2024-09-10T19:05:30-04:00September 11th, 2024|Featured, Investor News, News, Press Releases|0 Comments

Breaking News: Development Just In! Contributing Funding and a Significant Additional Tool to Combat PTSD and TBI Jackson Center, PA September 11, 2024 – Halberd Corporation (OTC-PINK: "HALB”), in coordination with Athena Telemedicine Partners (ATP), and Athena GTX, Inc., is pleased to announce a substantial contract award commitment. Defense Atomics Corporation agreed to engage with ...

Sep 9 2024

Halberd Corp. Issues Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

By Admin|2024-09-08T17:19:55-04:00September 9th, 2024|Featured, Investor News, Press Releases|0 Comments

Early Pilot Study Data from Veteran Volunteers is Compelling. Part B. Jackson Center, PA September 5, 2024 – Halberd Corporation (OTC-PINK: "HALB”) We hope you have had an opportunity to check out this Press release’s Part A. This Part B supplements that release of a few days ago. As always reach out to us if ...

Sep 4 2024

Halberd Letter to Shareholders – Patented LDN+ Evolves into WatchDawg™ for Veteran Suicide Reduction

By Admin|2024-09-03T18:06:24-04:00September 4th, 2024|Featured, Investor News, News, Press Releases, Update Letter|0 Comments

Early Pilot Study Data from Veteran Volunteers is Compelling. Jackson Center, PA September 4, 2024 – Halberd Corporation (OTC-PINK: "HALB”) To our shareholders. As promised, this is the second of three Press Releases on our recent progress. If you have not had a chance to review that last one, on the good news on our ...

Aug 26 2024

Halberd Corp. – Taking a Moment to Recenter Our Technical Progress

By Admin|2024-08-29T16:41:51-04:00August 26th, 2024|Investor News, Press Releases, Technology, Update Letter|0 Comments

Introducing Tri-axTM TBI Nasal Spray Treatment- the DoD selected our MSU-led pre-proposal, inviting us to submit a full application/proposal Jackson Center, PA August 26, 2024 – Halberd Corporation (OTC-PINK: "HALB”) This is the first of a series of three significant Press Releases we plan to issue shortly. Many of our investors have been voicing concern ...

Jul 24 2024

Halberd Corp’s (OTC: HALB) Groundbreaking Traumatic Brain Injury (TBI) Mitigation Nasal Spray Shows Promising Phase II Initial Test Results

By Admin|2024-07-23T18:32:56-04:00July 24th, 2024|Featured, Investor News, Press Releases|0 Comments

Jackson Center, PA July 24, 2024 – Halberd Corporation (OTC-PINK: "HALB”) has announced encouraging preliminary outcomes from its Phase II testing at Mississippi State University (MSU) of its Tri-AxTM nasal spray, aimed at mitigating the effects of traumatic brain injury (TBI) following head trauma. Dr. Russell Carr, the project's Principal Investigator, commented, “In the early ...

May 22 2024

Halberd/Athena GTX Research Promises a Much Brighter Future

By Admin|2024-05-21T16:43:28-04:00May 22nd, 2024|Featured, Investor News, News, Press Releases, Technology|0 Comments

Walt Disney once said, “All our dreams can come true if we have the courage to pursue them”. Jackson Center, PA May 22, 2024 – Halberd Corporation (OTC-PINK: "HALB”) in cooperation with Athena GTX, Inc is standing at the threshold of some major advancements to treat the issues facing not only our military but people ...

May 9 2024

Halberd’s Traumatic Brain Injury Treatment Projects Align with New U.S. House Bill

By Admin|2024-05-08T18:15:45-04:00May 9th, 2024|Featured, Investor News, News, Press Releases|0 Comments

Daniel J. Harvey and Adam Lambert Improving Servicemember Transition to Reduce Veteran Suicide Act, passed the U.S. House unanimously. Jackson Center, PA, May 9, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) two active programs for the treatment and mitigation of the negative effects of traumatic brain injury (TBI) align well with the newly passed bill in ...

Apr 30 2024

Halberd’s Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans

By Admin|2024-04-29T18:57:39-04:00April 30th, 2024|Featured, Investor News, Medical, News, Press Releases|0 Comments

LDN+ Drug Designed to Combat PTSD and Suicidal Ideation Jackson Center, PA, April 30, 2024 – Halberd Corporation (OTC-PINK: "HALB”) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot ...

Apr 4 2024

Halberd’s Patented Drug, LDN+, the Subject of a Limited Clinical Trial under an Innovative Four-company Cooperative Research and Development (CRADA) Contract.

By Admin|2024-04-04T17:47:08-04:00April 4th, 2024|Featured, Investor News, Medical, News, Press Releases|0 Comments

Jackson Center, PA, April 4, 2024 – Halberd Corporation’s (OTC-PINK: "HALB”) Patented LDN+ Drug hits an enormous milestone as it enters a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. Halberd Corporation's patented drug, LDN+, a combination of low-dose Naltrexone and Cyclobenzaprine, is a central part of a just ...

12 Next